ReviewNeuro-oncology practice2016
Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria.
Review in Neuro-oncology practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis.Korean journal of radiology · 2020Pooled it
- Diagnostic and Prognostic Value of Hypoxia PET in Glioma: A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Development and Evaluation of Automated Artificial Intelligence-Based Brain Tumor Response Assessment in Patients with Glioblastoma.AJNR. American journal of neuroradiology · 2025Article
- Saturation transfer (CEST and MT) MRI for characterization of U-87 MG glioma in the rat.NMR in biomedicine · 2025Article
- Results from a first-in-human phase I safety trial to evaluate the use of a vascularized pericranial/temporoparietal fascial flap to line the resection cavity following resection of newly diagnosed glioblastoma.Journal of neuro-oncology · 2024Article
- Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma.Heliyon · 2023Article
- The complementary role of MRI and FET PET in high-grade gliomas to differentiate recurrence from radionecrosis.Frontiers in nuclear medicine · 2023Article
- Article
- Conventional and Advanced Imaging Techniques in Post-treatment Glioma Imaging.Frontiers in radiology · 2022Review
- RDAU-Net: Based on a Residual Convolutional Neural Network With DFP and CBAM for Brain Tumor Segmentation.Frontiers in oncology · 2022Article
- Fully automated analysis combining [European journal of nuclear medicine and molecular imaging · 2021Article
- Shape matters: morphological metrics of glioblastoma imaging abnormalities as biomarkers of prognosis.Scientific reports · 2021Article
- Article
- Article
- Radiomics and Deep Learning from Research to Clinical Workflow: Neuro-Oncologic Imaging.Korean journal of radiology · 2020Review
- A Quantitative Assessment of Pre-Operative MRI Reports in Glioma Patients: Report Metrics and IDH Prediction Ability.Frontiers in oncology · 2020Article
- Integration of machine learning and mechanistic models accurately predicts variation in cell density of glioblastoma using multiparametric MRI.Scientific reports · 2019Article
- Earliest radiological progression in glioblastoma by multidisciplinary consensus review.Journal of neuro-oncology · 2018Article
- Current Clinical Brain Tumor Imaging.Neurosurgery · 2017Review
- A systematic review of the utility of amino acid PET in assessing treatment response to bevacizumab in recurrent high-grade glioma.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurately evaluating response in the treatment of high-grade gliomas presents considerable challenges. This review looks at the advancements made in response criteria while critically outlining remaining weaknesses, and directs our vision toward promising endpoints to come. The 2010 guidelines from the Response Assessment in Neuro-Oncology (RANO) working group have enhanced interpretation of clinical trials involving novel treatments for high-grade glioma. Yet, while the criteria are considered clinically applicable to high-grade glioma trials, as well as reasonably accurate and reproducible, RANO lacks sufficient detail for consistent implementation in certain aspects and leaves some issues from the original Macdonald guidelines unresolved. To provide the most accurate assessment of response to therapeutic intervention currently possible, it is essential that trial oncologists and radiologists not only have a solid understanding of RANO guidelines, but also proper insight into the inherent limitations of the criteria. With the expectation of improved data collection as a standard, the author anticipates that the next high-grade glioma response criteria updates will incorporate advanced MRI methods and quantitative tumor volume measurements, availing a more accurate interpretation of response in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.